<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219765</url>
  </required_header>
  <id_info>
    <org_study_id>010495</org_study_id>
    <secondary_id>CSTI571AFR01</secondary_id>
    <nct_id>NCT00219765</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients</brief_title>
  <official_title>Phase I/II Trial to Study the Dose, Tolerability and the Effectiveness of Imatinib in Combination With Daunorubicine and Cytarabine for Patients With Chronic Myelogenous Leukemia in Myeloid Acute Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      The aim of this phase I/II trial is to determine the dose of daunorubicine to be associated
      with cytarabine and Imatinib for induction therapy in patients with chronic myelogenous
      leukemia in myeloid acute phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design Imatinib: starting at day –3: 600mg/day; continuous administration In
      combination with cytarabine: continuous iv/24h: 100mg/m² ; 7 days and daunorubicine: 4 levels

      level 1: 0

      level 2: 15mg/m² ; 3 days

      level 3: 30mg/m² ; 3 days

      level 4: 45mg/m² ; 3 days
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2001</start_date>
  <completion_date>January 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the tolerability and the effectiveness of imatinib in combination with daunorubicine and cytarabine and to determine the recommended dose of daunorubicine to be associated with cytarabine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- To evaluate the survival without progression, the survival without event, the overall survival, the hematologic, cytogenetic and molecular responses at various check points.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- To evaluate duration of responses and failure to respond</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate 600 mg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CML Ph+ (assessed by cytogenetic or FISH)

          -  Acute phase with ≥ 20% bone marrow blasts (M0 to M6 , excluding M3)

          -  Age ≥ 18 year at inclusion

          -  PS grade 0 to 2 (ECOG)

          -  Adequate and organ function, defined as the following: total bilirubin &lt;1.5x uln, sgpt
             &lt;3x uln, creatinine &lt;1.5x uln.

          -  Informed consent signed up

        Exclusion Criteria:

          -  active malignancy other than CML or non-melanoma cancer of the skin

          -  current treatment with another investigational agent

          -  patients with grade 3/4 cardiac disease or any other serious concurrent medical
             condition.

          -  patients who are pregnant or nursing. All patients of childbearing potential must
             practice effective methods of contraception while on study.

          -  patients with mental illness or other condition precluding their ability to give
             informed consent or to comply with study requirements patients with performans status
             3-4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François GUILHOT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://lmc-cml.org/fr/</url>
    <description>French CML Group (FI-LMC) web-site</description>
  </link>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>November 25, 2005</last_update_submitted>
  <last_update_submitted_qc>November 25, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2005</last_update_posted>
  <keyword>CML</keyword>
  <keyword>Acute Phase</keyword>
  <keyword>Imatinib mesylate</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Daunorubicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

